文献速递痛风与晶体性关节病

免疫调节剂对pegloticase疗效与耐受性的影响:系统综述

The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review.
PubMed 文献 · Semin Arthritis Rheum · 2021-01-27

该系统综述检索PubMed及主要风湿病学会摘要数据库(2012-2020),纳入10篇文献共82例难治性痛风患者,接受免疫调节剂与pegloticase联合治疗,总体应答率为82.9%,提示免疫调节联合治疗可能显著提高pegloticase应答率。

要点

  • 联合免疫调节剂后pegloticase总体应答率达82.9%。
  • 甲氨蝶呤联合组应答率87.5%(35/40)。
  • 吗替麦考酚酯联合组应答率86.4%(19/22),单药对照组40%(4/10)。

核心结论

  • 已发表的报告提示,免疫调节联合治疗有可能显著提高未控制痛风患者中pegloticase的应答率。

研究设计与样本

  • 系统综述,检索PubMed及主要风湿病学会会议摘要数据库(2012-2020),纳入10篇文献共82例pegloticase联合免疫调节治疗的病例。

主要发现

  • 总体pegloticase应答率为82.9%。
  • 甲氨蝶呤联合组应答率为87.5%(35/40例)。
  • 吗替麦考酚酯联合组应答率为86.4%(19/22例),pegloticase单药(安慰剂)组为40%(4/10例)。
  • 硫唑嘌呤联合组应答率为63.6%(7/11例),来氟米特联合组为66.7%(4/6例)。
  • 1例联合环孢素者为应答者,2例联合多种免疫调节剂者均为应答者。

临床怎么用

  • 对于难治性或未控制痛风患者,可考虑在pegloticase治疗时联合免疫调节剂以降低抗药抗体形成、提高应答率。

局限性

  • 证据基于已发表的病例报告和会议摘要,非随机对照试验,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Pegloticase is a recombinant PEGylated uricase that converts relatively insoluble urate to highly water-soluble allantoin, which is readily excreted by the kidneys. It is the first and only biologic treatment indicated for refractory or uncontrolled gout. Clinical trials showed a 6-month pegloticase responder rate of 42%, with the non-responder rate largely being attributed to the development of high-titer anti-drug antibodies (ADAs) against pegloticase. Immunomodulation attenuates ADA formation to biologics in a number of autoimmune conditions, but their use with pegloticase for uncontrolled gout is less established. This systematic review examined published cases of refractory gout patients treated with immunomodulation in combination with pegloticase. METHODS: Published cases of immunomodulation with pegloticase were identified in a PubMed search and in abstract databases of major rheumatology society meetings (2012-2020). Duplicate and review articles were excluded, as were those that did not include cases of pegloticase use with immunomodulation. Cases with off-label pegloticase administration schedules were also excluded. Pegloticase response was defined according to each study's specified standard. RESULTS: Ten publications describing 82 cases of pegloticase use in the setting of immunomodulation were identified. Overall pegloticase response rate was 82.9%. Patients co-treated with an individual immunomodulator had the following response rates: methotrexate: 87.5% (35 of 40 patients), mycophenolate mofetil: 86.4% (19 of 22 patients vs. pegloticase monotherapy [placebo]: 40% [4 of 10 patients]), azathioprine: 63.6% (7 of 11 patients), and leflunomide: 66.7% (4 of 6 patients). A single patient was co-treated with cyclosporin and was a responder. The two patients treated with more than one immunomodulator were both responders. CONCLUSION: Published reports suggest that immunomodulation co-therapy has the potential to markedly improve pegloticase responder rates in patients with uncontrolled gout.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Keenan RT, Botson JK, Masri KR, et al. The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review. Semin Arthritis Rheum. 2021. PMID: 33601190. doi:10.1016/j.semarthrit.2021.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。